The absence of LPA receptor 2 reduces the tumorigenesis by Apc Min mutation in the intestine

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 299, Issue 5, 2010, Pages

  Lin, Songbai ^a   Lee, Sei Jung ^a   Shim, Hyunsuk ^a   Chun, Jerold ^b   Yun, C Chris ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Adenomatous polyposis coli; Familial adenomatous polyposis; Lysophosphatidic acid; Multiple intestinal neoplasia

Indexed keywords

BETA CATENIN; CYCLIN D1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KRUPPEL LIKE FACTOR 5; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 2; UNCLASSIFIED DRUG;

ADENOMA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; GENE MUTATION; MALE; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANALYSIS OF VARIANCE; ANIMAL; GENETICS; IMMUNOHISTOCHEMISTRY; INTESTINE; INTESTINE TUMOR; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ADENOMA; ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; GENES, APC; IMMUNOHISTOCHEMISTRY; INTESTINAL NEOPLASMS; INTESTINES; MICE; MICE, TRANSGENIC; MUTATION; RECEPTORS, LYSOPHOSPHATIDIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78149481269     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00321.2010     Document Type: Article

References (52)

1. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 103: 311-320, 2000.
2. Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, Lin ME, Teo ST, Park KE, Mosley AN, Chun J. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 50: 157-186, 2010.
3. Chun J. Lysophospholipid receptors: implications for neural signaling. Crit Rev Neurobiol 13: 151-168, 1999.
4. 2 (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa2. Mol Cell Biol 22: 6921-6929, 2002.
5. Daub H, Wallasch C, Lankenau A, Herrlich A, Ullrich A. Signal characteristics of G protein-transactivated EGF receptor. EMBO J 16: 7032-7044, 1997.
6. Delaunoit T, Limburg PJ, Goldberg RM, Lymp JF, Loftus EV Jr. Colorectal cancer prognosis among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 4: 335-342, 2006.
7. Deng W, Shuyu E, Tsukahara R, Valentine WJ, Durgam G, Gududuru V, Balazs L, Manickam V, Arsura M, VanMiddlesworth L, Johnson LR, Parrill AL, Miller DD, Tigyi G. The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury. Gastroenterology 132: 1834-1851, 2007.
8. Fang X, Yu S, Tanyi JL, Lu Y, Woodgett JR, Mills GB. Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor- mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 22: 2099-2110, 2002.
9. Fukushima N, Ishii I, Contos JJ, Weiner JA, Chun J. Lysophospholipid receptors. Annu Rev Pharmacol Toxicol 41: 507-534, 2001.
10. Gardiner TA, Gibson DS, de Gooyer TE, de la Cruz VF, McDonald DM, Stitt AW. Inhibition of tumor necrosis factor-alpha improves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopathy. Am J Pathol 166: 637-644, 2005.
11. Greijer A, Delis-van Diemen P, Fijneman R, Giles R, Voest E, van Hinsbergh V, Meijer G. Presence of HIF-1 and related genes in normal mucosa, adenomas and carcinomas of the colorectum. Virchows Archiv 452: 535-544, 2008.
12. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
13. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512, 1998.
14. Huang MC, Lee HY, Yeh CC, Kong Y, Zaloudek CJ, Goetzl EJ. Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G proteincoupled receptor (LPA2). Oncogene 23: 122-129, 2004.
15. Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 73: 321-354, 2004.
16. Karhausen J, Furuta GT, Tomaszewski JE, Johnson RS, Colgan SP, Haase VH. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest 114: 1098-1106, 2004.
17. Kim KS, Sengupta S, Berk M, Kwak YG, Escobar PF, Belinson J, Mok SC, Xu Y. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Res 66: 7983-7990, 2006.
18. Kingsbury MA, Rehen SK, Contos JJ, Higgins CM, Chun J. Nonproliferative effects of lysophosphatidic acid enhance cortical growth and folding. Nat Neurosci 6: 1292-1299, 2003.
19. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D. Identification of FAP locus genes from chromosome 5q21. Science 253: 661-665, 1991.
20. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87: 159-170, 1996.
21. Kitayama J, Shida D, Sako A, Ishikawa M, Hama K, Aoki J, Arai H, Nagawa H. Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res 6: R640-R646, 2004.
22. Lee J, Park SY, Lee EK, Park CG, Chung HC, Rha SY, Kim YK, Bae GU, Kim BK, Han JW, Lee HY. Activation of hypoxia-inducible factor-1α is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. Clin Cancer Res 12: 6351-6358, 2006.
23. Lin S, Wang D, Iyer S, Ghaleb AM, Shim H, Yang VW, Chun J, Yun CC. The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer. Gastroenterology 136: 1711-1720, 2009.
24. + exchanger 3 and fluid absorption via LPA5 and NHERF2. Gastroenterology 138: 649-658, 2010.
25. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, Yu S, Stephens LC, Cui X, Murrow G, Coombes K, Muller W, Hung MC, Perou CM, Lee AV, Fang X, Mills GB. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 15: 539-550, 2009.
26. McConnell BB, Bialkowska AB, Nandan MO, Ghaleb AM, Gordon FJ, Yang VW. Haploinsufficiency of Kruppel-like factor 5 rescues the tumor-initiating effect of the Apc(Min) mutation in the intestine. Cancer Res 69: 4125-4133, 2009.
27. Mills GB, May C, McGill M, Roifman CM, Mellors A. A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res 48: 1066-1071, 1988.
28. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3: 582-591, 2003.
29. Moolenaar WH, van Meeteren LA, Giepmans BN. The ins and outs of lysophosphatidic acid signaling. BioEssays 26: 870-881, 2004.
30. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275: 1787-1790, 1997.
31. Morin PJ, Vogelstein B, Kinzler KW. Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci USA 93: 7950-7954, 1996.
32. Moser AR, Dove WF, Roth KA, Gordon JI. The Min (multiple intestinal neoplasia) mutation: its effect on gut epithelial cell differentiation and interaction with a modifier system. J Cell Biol 116: 1517-1526, 1992.
33. Phelps RA, Chidester S, Dehghanizadeh S, Phelps J, Sandoval IT, Rai K, Broadbent T, Sarkar S, Burt RW, Jones DA. A two-step model for colon adenoma initiation and progression caused by APC loss. Cell 137: 623-634, 2009.
34. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, Vogelstein B, Kinzler KW. APC mutations occur early during colorectal tumorigenesis. Nature 359: 235-237, 1992.
35. Rhodes JM, Campbell BJ. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol Med 8: 10-16, 2002.
36. Rosenberg DW, Giardina C, Tanaka T. Mouse models for the study of colon carcinogenesis. Carcinogenesis 30: 183-196, 2009.
37. Rusovici R, Ghaleb A, Shim H, Yang VW, Yun CC. Lysophosphatidic acid prevents apoptosis of Caco-2 colon cancer cells via activation of mitogen-activated protein kinase and phosphorylation of Bad. Biochim Biophys Acta 1770: 1194-1203, 2007.
38. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29: 625-634, 2010.
39. Shah Y, M, Ito S, Morimura K, Chen C, Yim SH, Haase V, H, Gonzalez FJ. Hypoxia-inducible factor augments experimental colitis through an MIF-1 dependent inflammatory signaling cascade. Gastroenterology 134: 2036-2048, 2008.
40. Shida D, Kitayama J, Yamaguchi H, Okaji Y, Tsuno NH, Watanabe T, Takuwa Y, Nagawa H. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res 63: 1706-1711, 2003.
41. Shida D, Watanabe T, Aoki J, Hama K, Kitayama J, Sonoda H, Kishi Y, Yamaguchi H, Sasaki S, Sako A, Konishi T, Arai H, Nagawa H. Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer. Lab Invest 84: 1352-1362, 2004.
42. Sun R, Chen X, Yang VW. Intestinal-enriched Kruppel-like factor (Kruppel-like factor 5) is a positive regulator of cellular proliferation. J Biol Chem 276: 6897-6900, 2001.
43. Takahashi M, Fukuda K, Sugimura T, Wakabayashi K. β-Catenin is frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat colon tumors. Cancer Res 58: 42-46, 1998.
44. Taylor C, Colgan S. Hypoxia and gastrointestinal disease. J Mol Med 85: 1295-1300, 2007.
45. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426, 1999.
46. Weiner JA, Fukushima N, Contos JJ, Scherer SS, Chun J. Regulation of Schwann cell morphology and adhesion by receptor-mediated lysophosphatidic acid signaling. J Neurosci 21: 7069-7078, 2001.
47. Wu X, Tu X, Joeng KS, Hilton MJ, Williams DA, Long F. Rac1 activation controls nuclear localization of β-catenin during canonical Wnt signaling. Cell 133: 340-353, 2008.
48. Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, Kennedy AW, Belinson J, Markman M, Casey G. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. J Am Med Assoc 280: 719-723, 1998.
49. Yang M, Zhong WW, Srivastava N, Slavin A, Yang J, Hoey T, An S. G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the β-catenin pathway. Proc Natl Acad Sci USA 102: 6027-6032, 2005.
50. Yoshimura H, Dhar DK, Kohno H, Kubota H, Fujii T, Ueda S, Kinugasa S, Tachibana M, Nagasue N. Prognostic impact of hypoxiainducible factors 1α and 2α in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin Cancer Res 10: 8554-8560, 2004.
51. Yun CC, Sun H, Wang D, Rusovici R, Castleberry A, Hall RA, Shim H. LPA2 receptor mediates mitogenic signals in human colon cancer cells. Am J Physiol Cell Physiol 289: C2-C11, 2005.
52. Zhang H, Bialkowska A, Rusovici R, Chanchevalap S, Shim H, Katz JP, Yang VW, Yun CC. Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of Kruppel-like factor 5. J Biol Chem 282: 15541-15549, 2007.